News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,276 Results
Type
Article (41987)
Company Profile (435)
Press Release (665854)
Section
Business (208593)
Career Advice (2019)
Deals (35990)
Drug Delivery (102)
Drug Development (83467)
Employer Resources (170)
FDA (16382)
Job Trends (15069)
News (352473)
Policy (33019)
Tag
Academia (2624)
Alliances (50839)
Alzheimer's disease (1360)
Approvals (16354)
Artificial intelligence (214)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (329)
Breast cancer (231)
Cancer (1759)
Cardiovascular disease (138)
Career advice (1682)
CAR-T (127)
Cell therapy (374)
Clinical research (67028)
Collaboration (697)
Compensation (375)
COVID-19 (2623)
C-suite (167)
Data (1656)
Diabetes (216)
Diagnostics (6341)
Earnings (86672)
Employer resources (147)
Events (114378)
Executive appointments (578)
FDA (17301)
Funding (631)
Gene therapy (266)
GLP-1 (686)
Government (4444)
Healthcare (19097)
Infectious disease (2736)
Inflammatory bowel disease (127)
Interviews (310)
IPO (16740)
Job creations (3698)
Job search strategy (1432)
Layoffs (466)
Legal (7962)
Lung cancer (260)
Manufacturing (244)
Medical device (13410)
Medtech (13415)
Mergers & acquisitions (19617)
Metabolic disorders (580)
Neuroscience (1792)
NextGen: Class of 2025 (6750)
Non-profit (4545)
Northern California (2118)
Obesity (325)
Opinion (212)
Patents (164)
People (58203)
Phase I (21054)
Phase II (29593)
Phase III (21857)
Pipeline (728)
Postmarket research (2600)
Preclinical (8967)
Radiopharmaceuticals (257)
Rare diseases (343)
Real estate (6005)
Regulatory (22377)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1826)
Startups (3753)
United States (18958)
Vaccines (630)
Weight loss (227)
Date
Today (17)
Last 7 days (609)
Last 30 days (2643)
Last 365 days (35496)
2025 (4559)
2024 (36299)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54921)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (734)
Arizona (219)
Asia (38918)
Australia (6478)
California (4885)
Canada (1725)
China (403)
Colorado (221)
Connecticut (242)
Europe (84926)
Florida (692)
Georgia (165)
Illinois (471)
Indiana (262)
Maryland (759)
Massachusetts (3757)
Michigan (200)
Minnesota (340)
New Jersey (1374)
New York (1379)
North Carolina (897)
Northern California (2118)
Ohio (175)
Pennsylvania (1112)
South America (1107)
Southern California (1826)
Texas (717)
Utah (145)
Washington State (485)
708,276 Results for "esperion therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.
March 22, 2024
·
10 min read
FDA
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
March 25, 2024
·
2 min read
·
Nick Paul Taylor
Policy
Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit
Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.
January 4, 2024
·
2 min read
·
Tyler Patchen
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Windtree Therapeutics, Inc. Announces Reverse Stock Split
February 19, 2025
·
7 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Press Releases
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
February 4, 2025
·
7 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
February 3, 2025
·
7 min read
Press Releases
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
February 12, 2025
·
4 min read
Drug Development
Esperion-Daiichi Sankyo Partnership Saga Continues with Payment Spat
For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.
March 17, 2023
·
2 min read
·
Tristan Manalac
1 of 70,828
Next
